Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: Where do we stand, where do we go

Critical Reviews in Oncology/Hematology

Volumn 50, Issue 3, 2004, Pages 175-186

  Patel, Jyoti D ^a   Pasche, Boris ^a   Argiris, Athanassios ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

EGFR; Erlotinib; Gefitinib; Kinase inhibitors; Non small cell lung cancer

Indexed keywords

4 N ACETYLDINALINE; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CELECOXIB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; ISIS 3521; LONAFARNIB; NAVELBINE; PACLITAXEL; PEMETREXED; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; RITUXIMAB; TRASTUZUMAB;

ACNE; ANOREXIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CONJUNCTIVITIS; CYTOTOXICITY; DIARRHEA; DRUG ACTIVITY; DRY SKIN; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; TRANSAMINITIS; TUMOR GROWTH; VOMITING; XEROSTOMIA;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 2942594183     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.02.004     Document Type: Review

References (87)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin. 54:2004;8-29
2. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2000. Bethesda (MD): National Cancer Institute; 2003. http://seer.cancer. gov/csr/1975-2000.
3. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:2002;92-98
4. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
5. Hahn W.C., Counter C.M., Lundberg A.S., et al. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468
6. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 237:1962;1555-1562
7. Carpenter G., King L. Jr., Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature. 276:1978;409-410
8. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565
9. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 103:2000;211-225
10. Sartor C.I. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin Oncol. 27:2000;15-20. [discussion 92-100]
11. Brabender J., Danenberg K.D., Metzger R., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 7:2001;1850-1855
12. Pfeiffer P., Clausen P.P., Andersen K., et al. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer. 74:1996;86-91
13. Rusch V., Klimstra D., Venkatraman E., et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 3:1997;515-522
14. Hirsch F.R., Varella-Garcia M., Bunn P.A. Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 21:2003;3798-3807
15. Kris M.G., Natale R.B., Herbst R.S. an inhibitor of the epidermal growth facto receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA. 290:2003;2149-2158
16. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 21:2003;2237-2246
17. Perez-Soler R., Chachoua A., Huberman M., et al. A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, egfr-expressing, non-small cell lung cancer. Proc Am Soc Clin Oncol. 20:2001;A1235
18. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 3:1997;2703-2707
19. Burtness B.A., Li Y., Flood W., et al. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol. 21:2002;A901
20. Herbst R.S., Maddox A.M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 20:2002;3815-3825
21. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839 a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 20:2002;4292-4302
22. Nakagawa K., Tamura T., Negoro S., et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 14:2003;922-930
23. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 20:2002;2240-2250
24. Kris M., Herbst H., Rischin D., et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839, a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor. Lung Cancer. 29(Suppl 1):2000;72
25. Wakeling A.E., Guy S.P., Woodburn J.R., et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62:2002;5749-5754
26. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 20:2002;110-124
27. Rojo F., Tabernero J., Van Cutsem E., et al. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefinitib (ZD1839). Proc Am Soc Clin Oncol. 22:2003;A764
28. Malik S.N., Siu L.L., Rowinsky E.K., et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res. 9:2003;2478-2486
29. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279
30. Cella D., Eton D.T., Fairclough D.L., et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 55:2002;285-295
31. http://www.fda.gov/cder/foi/appletter/2003/21399ltr.pdf.
32. Inoue A., Saijo Y., Maemondo M., et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 361:2003;137-139
33. Cooper J.A.J., White D.A., Matthay R.A. Drug-induced pulmonary disease, part 1:cytotoxic drugs. Am Rev Respir Dis. 133:1986;321-340
34. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2000;2095-2103
35. Fossella F.V., DeVore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 18:2000;2354-2362
36. Huisman C., Smit E.F., Giaccone G., et al. Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: a review. J Clin Oncol. 18:2000;3722-3730
37. Massarelli E., Andre F., Liu D.D., et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small cell lung cancer. Lung Cancer. 39:2003;55-61
38. Hainsworth J.D., Burris H.A. 3rd, Litchy S., et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer. 89:2000;328-333
39. Ciardiello F., Caputo R., Bianco R., et al. Anti-tumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063
40. Ciardiello F., Caputo R., Borriello G., et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer. 98:2002;463-469
41. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 6:2000;4885-4892
42. Gonzalez-Larriba J.L., Giaccone G., van Oosterom A.T., et al. ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumours: final results of a phase I trial. Proc Am Soc Clin Oncol. 21:2002;A376
43. Miller V.A., Johnson D.H., Krug L.M., et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol. 21:2003;2094-2100
44. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT-1). Ann Oncol. 13(suppl. 5):2002;127
45. Johnson D.H., Herbst R., Giaconne G., et al. ZD1839 ("Iressa") in combinaton with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial. Ann Oncol. 13(suppl. 5):2002;127
46. Albain K.S., Green S.J., Ravdin P.M., et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol. 21:2002;A143
47. Betensky R.A., Louis D.N., Cairncross J.G. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol. 20:2002;2495-2499
48. Fandi A., Gatzemeier U., Smith R., et al. Final data from a pilot trial of gefitinib (ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): safety and pharmacokinetics. Proc Am Soc Clin Oncol. 22:2003;A2635
49. Rixe O., Lemarie E., Chomy F., et al. Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell-lung cancer (NSCLC): clinical results and biological monitoring. Proc Am Soc Clin Oncol. 22:2003;A2659
50. Kim E.S., Mauer A.M., Tran H.T., et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc Am Soc Clin Oncol. 22:2003;A2581
51. Mininberg E.D., Herbst R.S., Henderson T., et al. PhaseI/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 22:2003;A2521
52. Miller V.A., Patel J., Shah N., et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): preliminary results of a phase II trial. Proc Am Soc Clin Oncol. 22:2003;A2491
53. West H.L., Franklin W.A., Gumerlock P., et al. ZD1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): a preliminary report of SWOG S0126. Lung Cancer. 41:2003;S56. [O-187]
54. O'Connell J., Kris M.G., Gralla R.J., et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol. 4:1986;1604-1614
55. Borges M., Sculier J.P., Paesmans M., et al. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC). Lung Cancer. 16:1996;21-33
56. Cagle P.T., Mody D.R., Schwartz M.R. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res. 50:1990;6632-6635
57. Ollayos C.W., Riordan G.P., Rushin J.M. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med. 118:1994;630-632
58. Mollerup S., Jorgensen K., Berge G., et al. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer. 37:2002;153-159
59. Stabile L.P., Gaither Davis A.L., Gubish C.T., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor and β and show biological responses to estrogen. Cancer Res. 62:2002;2141-2150
60. Omoto Y., Kobayashi Y., Nishida K., et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun. 285:2001;340-347
61. Kato S., Endoh H., Masuhiro Y., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494
62. Kato S., Kitamoto T., Masuhiro Y., et al. Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology. 55:1998;5-10
63. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 17:2003;309-317
64. Marquez D.C., Lee J., Lin T., et al. Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine. 16:2001;73-81
65. Saltz L., Kies M., Abbruzzese J.L., et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol. 22:2003;A817
66. Clark GM, Pérez-Soler R, Siu L, et al. Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 2003;22.
67. Herbst R.S., Giaccone G., Schiller J., et al. Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy (CT) for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 22:2003;A2523
68. Giaccone G., Johnson D., Scagliotti G.V., et al. Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT-1 and 2). Proc Am Soc Clin Oncol. 22:2003;A2522
69. Bailey LR, Kris M, Wolf M, et al. Tumor epidermal growth factor receptor (EGFR) expression levels does not predict for response in patients (pts) receiving gefitinib ("Iressa," ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer (NSCLC) (2003) IDEAL-1 and 2. Proc Am Ass Cancer Res 2003;A1362.
70. Bishop P.C., Myers T., Robey R., et al. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene. 21:2002;119-127
71. Stoehlmacher J., Brabender J., Shirota Y., et al. Association between mRNA expression level of epidermal growth factor receptor (EGFR), immunohistochemistry (IHC) and response to the EGFR-inhibitor C225 in advanced colorectal carcinoma. Proc Am Soc Clin Oncol. 20:2001;A593
72. Natale R.B., Skarin A.T., Maddox A.-M. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL-2. Proc Am Soc Clin Oncol. 21:2002;A1167
73. Christensen J.G., Schreck R.E., Chan E., et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res. 7:2001;4230-4238
74. Johnson D.H., Arteaga C.L. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial? J Clin Oncol. 21:2003;2227-2229
75. Moasser M.M., Basso A., Averbuch S.D., et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61:2001;7184-7188
76. Cappuzzo F., Gregorc V., Rossi E., et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol. 21:2003;2658-2663
77. Bianco R., Shin I., Ritter C.A., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the anti-tumor action of EGFR tyrosine kinase inhibitors. Oncogene. 22:2003;2812-2822
78. Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 19:2001;32S-40S
79. Janmaat M.L., Kruyt F.A.E., Rodriguez J.A., et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 9:2003;2316-2326
80. Argiris A., Mittal M. Gefitinib as first-line compassionate use therapy for advanced non-small cell lung cancer. Lung Cancer. 43(3):2004;317-322
81. Smit E.F., Mattson K., von Pawel J., et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol. 14:2003;455-460
82. Williamson S.K., Crowley J.J., Lara P.N., et al. S0003: Paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) Trial. Proc Am Soc Clin Oncol. 22:2003;A2502
83. Lynch T.J., Raju R., Lind M., et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proc Am Soc Clin Oncol. 22:2003;A2504
84. Gatzemeier U., Groth G., Hirsh V., et al. Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non-small cell lung cancer overexpressing HER2: results of a randomised phase II study. Proc Am Soc Clin Oncol. 21:2002;A1185
85. Von Pawel J., Koschel G., Crino L., et al. Randomized phase II study of the oral histone deacetylase inhibitor CI-994 plus carboplatin (C) and paclitaxel (T) vs placebo (PBO) plus C/T in the first-line treatment of advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 22:2003;A2518
86. Smylie M., Mercier R., Aboulafia D., et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 20:2001;A1226
87. Bissett D., von Pawel J., Mercier R., et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 21:2002;A1183